Altimmune Inc. Faces Class Action Lawsuit Following Disappointing Phase 2b Trial Results and Stock Plunge

Reuters

Aug 19

Altimmune Inc. Faces Class Action Lawsuit Following Disappointing Phase 2b Trial Results and Stock Plunge

A class action lawsuit has been filed against Altimmune Inc., a clinical-stage biopharmaceutical company based in Gaithersburg, Maryland. The lawsuit is on behalf of investors who acquired publicly traded securities of Altimmune between August 10, 2023, and June 25, 2025. The litigation follows Altimmune's announcement on June 26, 2025, regarding the topline results from its IMPACT Phase 2b trial of Pemvidutide for treating metabolic dysfunction-associated steatohepatitis (MASH). The company reported a failure to achieve statistical significance in the fibrosis reduction primary endpoint, attributing it to a higher-than-expected placebo response. This announcement led to a significant 53.2% drop in Altimmune's stock price. Investors affected during the specified period have until October 6, 2025, to seek to be appointed as lead plaintiff representatives in the class action.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Altimmune Inc. published the original content used to generate this news brief via Newsfile (Ref. ID: 262938) on August 18, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/2560213882"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2560213882\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2560213882?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-19 03:24","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2560213882","market":"fut","top_or_hot":-1,"title":"Altimmune Inc. Faces Class Action Lawsuit Following Disappointing Phase 2b Trial Results and Stock Plunge","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Altimmune Inc. Faces Class Action Lawsuit Following Disappointing Phase 2b Trial Results and Stock Plunge\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        A class action lawsuit has been filed against Altimmune Inc., a clinical-stage biopharmaceutical company based in Gaithersburg, Maryland. The lawsuit is on behalf of investors who acquired publicly traded securities of Altimmune between August 10, 2023, and June 25, 2025. The litigation follows Altimmune's announcement on June 26, 2025, regarding the topline results from its IMPACT Phase 2b trial of Pemvidutide for treating metabolic dysfunction-associated steatohepatitis (MASH). The company reported a failure to achieve statistical significance in the fibrosis reduction primary endpoint, attributing it to a higher-than-expected placebo response. This announcement led to a significant 53.2% drop in Altimmune's stock price. Investors affected during the specified period have until October 6, 2025, to seek to be appointed as lead plaintiff representatives in the class action.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Altimmune Inc. published the original content used to generate this news brief via Newsfile (Ref. ID: 262938) on August 18, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Altimmune Inc. Faces Class Action Lawsuit Following Disappointing Phase 2b Trial Results and Stock Plunge</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAltimmune Inc. Faces Class Action Lawsuit Following Disappointing Phase 2b Trial Results and Stock Plunge\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-08-19 03:24</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Altimmune Inc. Faces Class Action Lawsuit Following Disappointing Phase 2b Trial Results and Stock Plunge\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        A class action lawsuit has been filed against Altimmune Inc., a clinical-stage biopharmaceutical company based in Gaithersburg, Maryland. The lawsuit is on behalf of investors who acquired publicly traded securities of Altimmune between August 10, 2023, and June 25, 2025. The litigation follows Altimmune's announcement on June 26, 2025, regarding the topline results from its IMPACT Phase 2b trial of Pemvidutide for treating metabolic dysfunction-associated steatohepatitis (MASH). The company reported a failure to achieve statistical significance in the fibrosis reduction primary endpoint, attributing it to a higher-than-expected placebo response. This announcement led to a significant 53.2% drop in Altimmune's stock price. Investors affected during the specified period have until October 6, 2025, to seek to be appointed as lead plaintiff representatives in the class action.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Altimmune Inc. published the original content used to generate this news brief via Newsfile (Ref. ID: 262938) on August 18, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4599","symbol_name":"减肥药","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250818:nNDL638Gny:1","article_id":"2560213882","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2560213882","pubTimestamp":1755545056,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"A class action lawsuit has been filed against Altimmune Inc., a clinical-stage biopharmaceutical company based in Gaithersburg, Maryland. The lawsuit is on behalf of investors who acquired publicly traded securities of Altimmune between August 10, 2023, and June 25, 2025. The litigation follows Altimmune's announcement on June 26, 2025, regarding the topline results from its IMPACT Phase 2b trial of Pemvidutide for treating metabolic dysfunction-associated steatohepatitis . The company reported a failure to achieve statistical significance in the fibrosis reduction primary endpoint, attributing it to a higher-than-expected placebo response. This announcement led to a significant 53.2% drop in Altimmune's stock price. Investors affected during the specified period have until October 6, 2025, to seek to be appointed as lead plaintiff representatives in the class action.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT str","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4599":"减肥药","LU1878469433.USD":"THREADNEEDLE (LUX) - AMERICAN SMALLER COMPANIES \"A\" (USD) ACC","BK4139":"生物科技","ALT":"Altimmune, Inc."},"translate_title":"Altimmune Inc.因2b期试验结果令人失望和股价暴跌而面临集体诉讼","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ALT":0.9},"content_text":"Altimmune Inc. Faces Class Action Lawsuit Following Disappointing Phase 2b Trial Results and Stock Plunge\n    \n\n        A class action lawsuit has been filed against Altimmune Inc., a clinical-stage biopharmaceutical company based in Gaithersburg, Maryland. The lawsuit is on behalf of investors who acquired publicly traded securities of Altimmune between August 10, 2023, and June 25, 2025. The litigation follows Altimmune's announcement on June 26, 2025, regarding the topline results from its IMPACT Phase 2b trial of Pemvidutide for treating metabolic dysfunction-associated steatohepatitis (MASH). The company reported a failure to achieve statistical significance in the fibrosis reduction primary endpoint, attributing it to a higher-than-expected placebo response. This announcement led to a significant 53.2% drop in Altimmune's stock price. Investors affected during the specified period have until October 6, 2025, to seek to be appointed as lead plaintiff representatives in the class action.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Altimmune Inc. published the original content used to generate this news brief via Newsfile (Ref. ID: 262938) on August 18, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"policyRegulatory,event","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}